CD274 and neoplasm: Furthermore, BSO-CAT@MOF-199@DDM (BCMD) has shown significant potential to enhance the efficacy of anti-tumor immunotherapy when combined with the immune checkpoint inhibitor α-PD-L1 (Huang et al., 2023).